Argenx stock edges higher as September investor conferences loom

Argenx stock continues to trade in a high four-digit band, with argenx SE (ISIN NL0010832176) closing at 1,031.66 dollars on its Nasdaq listing as of August 31, 2026, up 0.83% on the day according to a recent market snapshot dated August 31, 2026.

Stock price and market capitalization in focus

According to recent Nasdaq trading data compiled by Yahoo Finance, argenx SE ADRs under the ticker ARGX closed at 1,031.66 dollars on August 31, 2026, after gaining 8.45 dollars or 0.83% versus the previous close of 1,023.21 dollars.

The latest market capitalization overview from CompaniesMarketCap puts Argenx at 65.21 billion dollars as of August 2026, up from 63.27 billion dollars on August 25, 2026, highlighting how the rising share price has added almost 1.94 billion dollars in equity value over a matter of days.

Analyst context and recent earnings backdrop

A recent corporate news overview on Ad-Hoc News notes that Argenx stock most recently closed at 1,023.21 dollars on its US Nasdaq listing as of August 28, 2026, at 4:00 p.m. ET.

The same overview cites an analyst alert summarizing Nasdaq trading on August 31, 2026, showing Argenx shares trading intraday at 1,015.95 dollars, down 7.26 dollars or roughly 0.7% during midday, indicating that the stock has seen modest day-to-day fluctuations around the 1,000 dollar threshold.

In euro terms, live exchange data for the company’s European listing on Euronext Brussels, as referenced by Ad-Hoc News using recent exchange data, shows a trade at 895.20 euros at 17:37:02 local time, illustrating that the stock’s European quotation also sits in a high triple-digit band and underlining the dual listing between Nasdaq and Euronext Brussels.

Upcoming investor conferences in September

Fresh visibility for Argenx among institutional investors is on the agenda in September 2026, as management prepares to participate in multiple healthcare investor conferences.

As detailed in an investor communication carried by Yahoo Finance on September 1, 2026, Argenx plans to join the Wells Fargo 21st Annual Healthcare Conference with a fireside chat scheduled for September 8, 2026 at 9:30 a.m. ET in Boston.

The same announcement notes that Argenx will also participate in the Morgan Stanley 24th Annual Global Healthcare Conference, with a fireside chat booked for September 14, 2026 at 9:15 a.m. ET in New York, giving the company two high-profile opportunities to update investors on its strategy, pipeline and financial performance.

Representative product and core business

Argenx’s core business centers on antibody-based therapies in immunology, with the company best known for its development of the FcRn-targeting antibody efgartigimod, marketed under the brand name Vyvgart in several autoimmune indications.

According to Argenx’s positioning as a global immunology innovation company, the Vyvgart franchise is central to its revenue generation, with the drug used to treat conditions such as generalized myasthenia gravis and providing a platform for expansion into additional autoimmune diseases.

Stock level for investors to watch

For investors assessing Argenx stock as of late August and early September 2026, the latest completed closing price stands at 1,031.66 dollars on Nasdaq as of August 31, 2026, with the shares also quoted on Euronext Brussels and supported by a market capitalization around 65.21 billion dollars based on August 2026 data.